We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-3.19%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$522M
AUM Growth
-$148M
Cap. Flow
-$183M
Cap. Flow %
-35.1%
Top 10 Hldgs %
68.85%
Holding
172
New
42
Increased
30
Reduced
27
Closed
64

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$18.7M
2
AZN icon
AstraZeneca
AZN
+$11.5M
3
XWEL icon
XWELL
XWEL
+$3.81M
4
RVPH
REVIVA PHARMA HLDGS INC
RVPH
+$3.63M
5
CVM icon
CEL-SCI Corp
CVM
+$2.66M

Top Sells

Rank Stock Value
1
SRNE
Sorrento Therapeutics, Inc.
SRNE
+$4.87M
2
IMMU
Immunomedics Inc
IMMU
+$4.25M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$4.12M
4
SPI
SPI Energy Co., Ltd. Ordinary Shares
SPI
+$3.57M
5
RMTI icon
Rockwell Medical
RMTI
+$3.04M

Sector Composition

Rank Sector Weight
1 Healthcare 17.64%
2 Industrials 0.71%
3 Technology 0.22%
4 Consumer Discretionary 0.14%
5 Consumer Staples 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GOVXW
76
DELISTED
GeoVax Labs Warrants
GOVXW
$283K 0.05%
275,695
+84,038
+44% +$70.7K
PRFX icon
77
PRF Technologies Ltd
PRFX
$3.01M
$275K 0.05%
51
-320
-86% -$1.76M
LFWD icon
78
ReWalk Robotics
LFWD
$20M
$254K 0.05%
+2,290
New +$243K
ATHE
79
Alterity Therapeutics
ATHE
$80.5M
$249K 0.05%
+18,584
New +$293K
SPI
80
PUT
DELISTED
SPI Energy Co., Ltd. Ordinary Shares
SPI
$238K 0.05%
+302
New +$2.53K
ATXS
81
DELISTED
Astria Therapeutics
ATXS
$231K 0.04%
+18,004
New +$321K
PHAS
82
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$218K 0.04%
65,000
-14,470
-18% -$51.8K
BIOC
83
PUT
DELISTED
Biocept, Inc.
BIOC
$211K 0.04%
+16
New +$2.28K
CYTHW
84
DELISTED
Cyclo Therapeutics, Inc. Warrant
CYTHW
$208K 0.04%
+193,012
New +$238K
BMY.RT
85
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$207K 0.04%
+300,000
New +$639K
HEPA
86
PUT
DELISTED
Hepion Pharmaceuticals
HEPA
$201K 0.04%
1
– –
GOVX icon
87
GeoVax Labs
GOVX
$3.64M
$191K 0.04%
150
-492
-77% -$572K
EVOK
88
DELISTED
Evoke Pharma
EVOK
$168K 0.03%
451
+296
+191% +$153K
PTE
89
DELISTED
PolarityTE, Inc. Common Stock
PTE
$163K 0.03%
+9,568
New +$202K
PTE
90
PUT
DELISTED
PolarityTE, Inc. Common Stock
PTE
$163K 0.03%
96
-97
-50% -$2.05K
BIOC
91
DELISTED
Biocept, Inc.
BIOC
$140K 0.03%
+1,053
New +$150K
EMAN
92
PUT
DELISTED
eMagin Corporation
EMAN
$137K 0.03%
829
-343
-29% -$441
INO icon
93
CALL
Inovio Pharmaceuticals
INO
$85.6M
$114K 0.02%
+11
New +$1.46K
TIO
94
DELISTED
Tingo Group, Inc. Common Stock
TIO
$111K 0.02%
+53,559
New +$119K
RKDA icon
95
Arcadia Biosciences
RKDA
$1.42M
$82K 0.02%
813
-6,072
-88% -$741K
DMK
96
PUT
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$76K 0.01%
22
– –
RKDA icon
97
PUT
Arcadia Biosciences
RKDA
$1.42M
$61K 0.01%
+6
New +$732
NSPR icon
98
InspireMD
NSPR
$31.4M
$60K 0.01%
11,654
-4,606
-28% -$24.4K
ASXC
99
PUT
DELISTED
Asensus Surgical, Inc.
ASXC
$53K 0.01%
855
+61
+8% +$28
RDGT
100
Ridgetech Inc
RDGT
$692K
$51K 0.01%
1
– –
2 3
4
5 6

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q4 2020 Portfolio in Review

As of Q4 2020, Sabby Management held 172 positions worth $522M, down 22% from $670M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Sabby Management withdrew a net $183M in Q4 2020, closing 64 positions and reducing 27 holdings. Its most notable exit was Sorrento Therapeutics, Inc., an estimated $4.87M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 12% a quarter earlier, followed by Industrials and Technology.

Against the trend, Sabby Management opened a new position in REVIVA PHARMA HLDGS INC worth $3.13M.

  • Sabby Management's largest Q4 2020 buy was REVIVA PHARMA HLDGS INC: 17,915 shares worth $3.13M.
  • Sabby Management added most to Biogen in Q4 2020, an estimated $18.7M increase.
  • Sabby Management's biggest Q4 2020 reduction was Rockwell Medical, cutting an estimated $3.04M.
  • Sabby Management fully exited Sorrento Therapeutics, Inc. in Q4 2020, selling an estimated $4.87M.
  • Sabby Management's ten largest holdings make up 69% of its $522M portfolio in Q4 2020.
  • Sabby Management opened 42 new positions and closed 64 in Q4 2020.
  • Sabby Management's portfolio value fell 22% quarter-over-quarter to $522M.

Based on Sabby Management's 13F filing for Q4 2020, filed 16 Feb 2021.